[go: up one dir, main page]

JO3441B1 - طرق لاصلاح مثبطات انزيم jak والمركبات الوسيطة المتعلقة به - Google Patents

طرق لاصلاح مثبطات انزيم jak والمركبات الوسيطة المتعلقة به

Info

Publication number
JO3441B1
JO3441B1 JOP/2010/0010A JOP20100010A JO3441B1 JO 3441 B1 JO3441 B1 JO 3441B1 JO P20100010 A JOP20100010 A JO P20100010A JO 3441 B1 JO3441 B1 JO 3441B1
Authority
JO
Jordan
Prior art keywords
repairing
methods
jak inhibitors
related intermediates
pyrimidines
Prior art date
Application number
JOP/2010/0010A
Other languages
English (en)
Inventor
Qiyan Lin
Brian W Metcalf
Haisheng Wang
David Meloni
Jiacheng Zhou
Yongchun Pan
Michael Xia
Mei Li
Tai-Yuen Yue
Pingli Liu
James D Rodgers
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3441(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corp filed Critical Incyte Corp
Application granted granted Critical
Publication of JO3441B1 publication Critical patent/JO3441B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
    • C07F7/083—Syntheses without formation of a Si-C bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يتعلق الاكتشاف الحالي بطرق لتحضير بايريمدينات <span dir="LTR">[2,3-<em>d</em>]</span> بايرولو بايرازوليل مستبدلة الجزيئات غير منطبقة مرآويا خاصة بالصيغة <span dir="LTR">III</span> والمركبات الوسيطة التوليفية الصناعية المتعلقة بها. البايريمدينات <span dir="LTR">[2,3-<em>d</em>]</span> بايرولو بايرازوليل مستبدلة الجزيئات غير المنطبقة مرآويا مفيدة كمثبطات لعائلة مستقبِل كاينيز جانوس لبروتين كاينيز تايروزين لمعالجة الامراض الالتهابية واضطرابات التشعب النخاعي العظمي وغير ذلك من الامراض.
JOP/2010/0010A 2009-01-15 2010-01-14 طرق لاصلاح مثبطات انزيم jak والمركبات الوسيطة المتعلقة به JO3441B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14499109P 2009-01-15 2009-01-15

Publications (1)

Publication Number Publication Date
JO3441B1 true JO3441B1 (ar) 2019-10-20

Family

ID=42026219

Family Applications (3)

Application Number Title Priority Date Filing Date
JOP/2019/0230A JOP20190230A1 (ar) 2009-01-15 2009-01-15 طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
JOP/2019/0231A JOP20190231A1 (ar) 2009-01-15 2009-01-15 طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
JOP/2010/0010A JO3441B1 (ar) 2009-01-15 2010-01-14 طرق لاصلاح مثبطات انزيم jak والمركبات الوسيطة المتعلقة به

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JOP/2019/0230A JOP20190230A1 (ar) 2009-01-15 2009-01-15 طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
JOP/2019/0231A JOP20190231A1 (ar) 2009-01-15 2009-01-15 طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به

Country Status (29)

Country Link
US (10) US8410265B2 (ar)
EP (3) EP4501410A3 (ar)
JP (6) JP5650662B2 (ar)
KR (7) KR102220482B1 (ar)
CN (5) CN108395433B (ar)
AR (2) AR082747A1 (ar)
AU (5) AU2010204772B2 (ar)
BR (3) BRPI1006794B1 (ar)
CA (2) CA2749483C (ar)
CL (3) CL2011001668A1 (ar)
CO (1) CO6400137A2 (ar)
EA (3) EA201991779A3 (ar)
EC (1) ECSP11011268A (ar)
ES (2) ES3001142T3 (ar)
IL (7) IL214061A (ar)
JO (3) JOP20190230A1 (ar)
MA (1) MA33038B1 (ar)
MX (5) MX357874B (ar)
MY (3) MY163540A (ar)
NZ (5) NZ739757A (ar)
PE (4) PE20171102A1 (ar)
PH (1) PH12016502060A1 (ar)
PL (2) PL3272738T3 (ar)
PT (2) PT2398774T (ar)
SG (3) SG172468A1 (ar)
TN (1) TN2011000329A1 (ar)
TW (7) TWI720517B (ar)
WO (1) WO2010083283A2 (ar)
ZA (1) ZA201104909B (ar)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060106020A1 (en) * 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
PL1966202T3 (pl) 2005-12-13 2012-02-29 Incyte Holdings Corp Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
CN103524509B (zh) 2007-06-13 2016-03-02 因塞特控股公司 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐
UA104849C2 (uk) * 2007-11-16 2014-03-25 Інсайт Корпорейшн 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
AR076920A1 (es) * 2009-05-22 2011-07-20 Incyte Corp 3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)octano-o heptano--nitrilo como inhibidores de jak
MX2011012353A (es) 2009-05-22 2011-12-14 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EA021478B1 (ru) * 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
AU2011217961B2 (en) * 2010-02-18 2016-05-05 Incyte Holdings Corporation Cyclobutane and methylcyclobutane derivatives as Janus kinase inhibitors
LT3354652T (lt) 2010-03-10 2020-09-25 Incyte Holdings Corporation Piperidin-4-il azetidino dariniai kaip jak1 inhibitoriai
SG184870A1 (en) 2010-04-14 2012-11-29 Array Biopharma Inc 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
TWI499421B (zh) 2010-05-21 2015-09-11 Incyte Corp Ｊａｋ抑制劑的局部製劑
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
MX344478B (es) 2010-11-19 2016-12-16 Incyte Holdings Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de janus cinasas (jak).
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9993480B2 (en) 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
CN102690281A (zh) * 2011-03-22 2012-09-26 上海药明康德新药开发有限公司 1-甲基4-吡唑频哪醇酯的合成方法
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PH12019502809B1 (en) 2012-06-13 2024-04-24 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
EP3882249B1 (en) 2012-06-15 2025-05-14 Sun Pharmaceutical Industries, Inc. Deuterated derivatives of ruxolitinib
US20150148292A1 (en) 2012-07-09 2015-05-28 Emory University Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
EA031716B1 (ru) 2012-08-17 2019-02-28 Консерт Фармасьютикалс, Инк. Дейтерированный барицитиниб
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
US20150284380A1 (en) 2012-10-31 2015-10-08 Bayer Cropscience Ag Novel heterocyclic compounds as pest control agents
EP2917221A1 (en) 2012-11-01 2015-09-16 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
IL297429A (en) 2012-11-15 2022-12-01 Incyte Holdings Corp Sustained release dosage forms of roxolitinib
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
HRP20211922T1 (hr) 2013-03-06 2022-03-04 Incyte Holdings Corporation Postupci i intermedijeri za pripravu jak inhibitora
SMT201800127T1 (it) 2013-04-19 2018-05-02 Incyte Holdings Corp Eterocilci biciclici come inibitori di fgfr
SMT202500397T1 (it) 2013-05-17 2025-11-10 Incyte Holdings Corp Derivati bipirazolici come inibitori di jak
PE20160223A1 (es) 2013-08-07 2016-04-27 Incyte Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1
CN103601749B (zh) * 2013-11-26 2016-04-27 大连联化化学有限公司 一种1-烷基吡唑-4-硼酸频哪醇酯的合成方法
UA117040C2 (uk) 2013-12-05 2018-06-11 Пфайзер Інк. ПІРОЛО[2,3-d]ПІРИМІДИНІЛ-, ПІРОЛО[2,3-b]ПІРАЗИНІЛ- ТА ПІРОЛО[2,3-d]ПІРИДИНІЛАКРИЛАМІДИ
CN104860950A (zh) * 2014-02-24 2015-08-26 重庆医药工业研究院有限责任公司 一种制备4-氯吡咯[2,3-d]并嘧啶的方法
HUE051625T2 (hu) 2014-04-08 2021-03-29 Incyte Corp B-sejtes rosszindulatú daganatok kezelése JAK és PI3K inhibitorok kombinációjával
TW201625643A (zh) 2014-04-30 2016-07-16 英塞特公司 製備ｊａｋ１抑制劑之方法及其新形式
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
CN105218548A (zh) * 2014-06-09 2016-01-06 上海海和药物研究开发有限公司 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途
SMT202200285T1 (it) 2014-08-11 2022-09-14 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk, un inibitore di pd-1 e/o un inibitore di pd-l1
ES2900184T3 (es) 2014-08-11 2022-03-16 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
WO2016035014A1 (en) * 2014-09-01 2016-03-10 Sun Pharmaceutical Industries Limited Processes for the preparation of ruxolitinib phosphate
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CZ2014773A3 (cs) * 2014-11-10 2016-05-18 Zentiva, K.S. Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu
CN104496904B (zh) * 2014-11-28 2017-01-11 上海北卡医药技术有限公司 一种鲁索利替尼中间体的合成方法
WO2016088094A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Process for the preparation of baricitinib and an intermediate thereof
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
SG10201913036RA (en) 2015-02-20 2020-02-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CZ2015496A3 (cs) 2015-07-14 2017-01-25 Zentiva, K.S. Krystalické formy solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a jejich příprava
CN106397443A (zh) * 2015-07-17 2017-02-15 浙江九洲药业股份有限公司 一种吡咯嘧啶类衍生物中间体的制备方法
HU230805B1 (hu) * 2015-12-23 2018-06-28 Egis Gyógyszergyár Zrt Eljárás és köztitermék baricitinib előállítására
CN111763209B (zh) * 2015-12-31 2021-12-03 正大天晴药业集团股份有限公司 一种芦可替尼的合成工艺
CZ201629A3 (cs) 2016-01-22 2017-08-02 Zentiva, K.S. Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy
ES2877200T3 (es) * 2016-01-26 2021-11-16 Hangzhou Bangshun Pharmaceutical Co Ltd Derivado azacíclico de cinco miembros de pirrolopirimidina y aplicación del mismo
CN107226814A (zh) * 2016-03-23 2017-10-03 罗欣生物科技（上海）有限公司 一种巴瑞克替尼中间体的制备方法
CN109069493A (zh) 2016-05-04 2018-12-21 康塞特医药品有限公司 用氘代jak抑制剂治疗脱毛障碍
CN107513069A (zh) * 2016-06-16 2017-12-26 正大天晴药业集团股份有限公司 手性吡咯并嘧啶化合物的制备方法
CN106188116B (zh) * 2016-07-14 2018-02-06 沧州普瑞东方科技有限公司 一种合成吡唑‑4‑硼酸频那醇酯的方法
CN107722012B (zh) 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法
CN107759601B (zh) * 2016-08-23 2020-09-11 苏州旺山旺水生物医药有限公司 一种jak抑制剂及其盐的制备方法
CN107759623B (zh) * 2016-08-23 2020-08-14 苏州旺山旺水生物医药有限公司 Jak抑制剂的中间体及其制备方法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107501154B (zh) * 2017-09-13 2020-02-11 浙江普洛康裕制药有限公司 (s)-1-(2-氯乙酰基)吡咯烷-2-甲腈的合成方法
CN109651424B (zh) * 2017-10-11 2021-01-22 新发药业有限公司 一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
EP3746429B1 (en) 2018-01-30 2022-03-09 Incyte Corporation Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
JP7736431B2 (ja) 2018-02-16 2025-09-09 インサイト・コーポレイション サイトカイン関連障害を治療するためのｊａｋ１経路阻害薬
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
BR112020019814A2 (pt) 2018-03-30 2021-01-05 Incyte Corporation Tratamento de hidradenite supurativa usando inibidores jak
JP7378420B2 (ja) 2018-04-13 2023-11-13 インサイト・コーポレイション 移植片対宿主病のバイオマーカー
JP2021523121A (ja) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤の固体形態及びその調製プロセス
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
IL278889B2 (en) 2018-06-01 2025-11-01 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
SG11202101785UA (en) * 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc Process for preparing jak inhibitors and intermediates thereof
WO2020072870A1 (en) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Co-crystal forms of baricitinib
AU2019374072A1 (en) 2018-10-31 2021-05-27 Incyte Corporation Combination therapy for treatment of hematological diseases
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
US12325707B2 (en) * 2019-02-06 2025-06-10 Sun Pharmaceutical Industries, Inc. Process for preparing enantiomerically enriched JAK inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110028509B (zh) * 2019-05-27 2020-10-09 上海勋和医药科技有限公司 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN110538183B (zh) * 2019-10-09 2021-05-04 吉林大学 一种预防和治疗小儿湿疹的组合物及其制备方法
WO2021072098A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
JP2022551649A (ja) 2019-10-10 2022-12-12 インサイト・コーポレイション 移植片対宿主病のバイオマーカー
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
PH12022551052A1 (en) 2019-11-22 2023-05-29 Incyte Corp Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of fgfr repressors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
ES2998487T3 (en) 2020-06-02 2025-02-20 Incyte Corp Processes of preparing a jak1 inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN111790439B (zh) * 2020-07-29 2022-12-27 成都能特科技发展有限公司 一种手性二级胺二苯基膦芳甲酰胺双功能催化剂及其制备方法与应用
CN116348467A (zh) * 2020-08-12 2023-06-27 康塞特医药品有限公司 用于制备对映异构体富集的jak抑制剂的方法
CR20230130A (es) 2020-08-18 2023-07-13 Incyte Corp Proceso e intermedios para preparar un inhibidor de jak1
CN116761792A (zh) * 2020-08-18 2023-09-15 因赛特公司 用于制备jak抑制剂的方法和中间体
PE20231743A1 (es) 2020-08-18 2023-10-31 Incyte Corp Proceso e intermediarios para preparar un inhibidor de jak
KR20230093504A (ko) 2020-10-28 2023-06-27 썬 파마슈티칼 인더스트리즈 인코포레이티드 중수소화된 jak 억제제를 이용한 탈모 장애의 치료를 위한 요법
EP4259131A1 (en) 2020-12-08 2023-10-18 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
CN112625030A (zh) * 2020-12-25 2021-04-09 杭州澳赛诺生物科技有限公司 一种一锅法合成n-保护3-溴代吡唑的合成方法
CN114853760B (zh) * 2021-02-03 2025-12-05 南京正大天晴制药有限公司 一种芦可替尼中间体的制备方法
CN114907353A (zh) * 2021-02-09 2022-08-16 明慧医药（杭州）有限公司 一种前药化合物及其制备方法和用途
CN112876503B (zh) * 2021-03-18 2022-04-29 中国科学院兰州化学物理研究所 用于癌症硼中子俘获治疗药物的硼酸盐化合物及其制备
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
SMT202500486T1 (it) 2021-05-03 2026-01-12 Incyte Corp Inibitori del percorso di jak1 per il trattamento di prurigo nodularis
CN113292569A (zh) * 2021-05-25 2021-08-24 常州制药厂有限公司 一种jak抑制剂的制备方法
CN113264936B (zh) * 2021-05-25 2022-08-09 常州制药厂有限公司 一种jak抑制剂关键中间体及其制备方法
JP2024522188A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023288197A1 (en) * 2021-07-12 2023-01-19 Incyte Corporation Process and intermediates for preparing baricitinib
CA3224493A1 (en) * 2021-07-20 2023-01-26 Lichun Feng External anti-inflammatory coupling compound drug, and preparation method therefor and use thereof
CN118159272A (zh) 2021-08-11 2024-06-07 太阳医药工业公司 用氘化的jak抑制剂来治疗脱发病症
WO2023018954A1 (en) 2021-08-12 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
WO2023042224A1 (en) * 2021-09-18 2023-03-23 Natco Pharma Limited An improved process for the preparation of ruxolitinib phosphate
CN114044777B (zh) * 2022-01-10 2022-04-19 南京佰麦生物技术有限公司 一种磷酸芦可替尼的制备方法
IL316549A (en) 2022-05-04 2024-12-01 Sun Pharmaceutical Ind Inc Dosing regimens for treatment with dual JAK inhibitors
WO2023223253A1 (en) * 2022-05-19 2023-11-23 Glenmark Life Sciences Limited Process for preparation of ruxolitinib
CN114805368B (zh) * 2022-05-25 2023-12-01 山东诺明康药物研究院有限公司 一种芦克替尼的制备方法
CN115028638A (zh) * 2022-06-09 2022-09-09 安徽大学 一种鲁索替尼中间体的制备方法
CN117384163B (zh) * 2022-07-05 2026-02-17 盛世泰科生物医药技术(苏州)股份有限公司 一种含偕二氟基的化合物及其制备方法和用途
IL314750A (en) * 2022-08-22 2024-10-01 Granules India Ltd IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB
US20240166654A1 (en) * 2022-11-11 2024-05-23 Zhejiang Ausun Pharmaceutical Co., Ltd. Ruxolitinib crystal and pharmaceutical composition thereof
CN118255768A (zh) * 2022-12-26 2024-06-28 上海科胜药物研发有限公司 一种jak抑制剂及其中间体的制备方法
CN116082382B (zh) * 2023-02-13 2025-11-21 上海瀚合瑞医药科技有限公司 芦可替尼关键中间体的制备方法
CN118852013B (zh) * 2023-04-28 2025-09-26 武汉人福创新药物研发中心有限公司 一种芦可替尼及其中间体的制备方法
CN121194977A (zh) 2023-09-04 2025-12-23 印度颗粒有限公司 用于制备芦可替尼及其新晶型的改良方法
US12364699B2 (en) 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
CN117946120A (zh) * 2024-01-30 2024-04-30 正大制药（青岛）有限公司 一种磷酸芦可替尼有关物质a的制备方法
CN118047782A (zh) * 2024-02-06 2024-05-17 南京道尔医药研究院有限公司 制备芦可替尼中间体的方法
US12247034B1 (en) * 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate
CN118994172A (zh) * 2024-09-12 2024-11-22 广州科锐特生物科技有限公司 一种磷酸芦可替尼的制备方法
CN119528911B (zh) * 2024-10-21 2025-11-28 南通常佑药业科技有限公司 一种芦可替尼的制备方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2985589A (en) 1957-05-22 1961-05-23 Universal Oil Prod Co Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets
JPS5519438A (en) 1978-07-26 1980-02-12 Mitsubishi Electric Corp Brazing method
US4402832A (en) 1982-08-12 1983-09-06 Uop Inc. High efficiency continuous separation process
US4498991A (en) 1984-06-18 1985-02-12 Uop Inc. Serial flow continuous separation process
JP2513001B2 (ja) * 1988-11-01 1996-07-03 山川薬品工業株式会社 光学活性テトラヒドロフラン−２−カルボン酸のラセミ化方法
DE4038356A1 (de) * 1990-12-01 1992-06-04 Bayer Ag Verfahren zur racemisierung von optisch aktiven l-aryl-alkylaminen
JPH04308556A (ja) * 1991-04-05 1992-10-30 Hokuriku Seiyaku Co Ltd 光学活性なベンジルアルコール誘導体のラセミ化方法
JPH06122686A (ja) 1992-10-12 1994-05-06 Fujisawa Pharmaceut Co Ltd ラセミ体の光学分割法
JPH07247286A (ja) 1994-01-18 1995-09-26 Sankyo Co Ltd 含窒素環状化合物の光学分割方法
US5630943A (en) 1995-11-30 1997-05-20 Merck Patent Gesellschaft Mit Beschrankter Haftung Discontinuous countercurrent chromatographic process and apparatus
GB9602516D0 (en) * 1996-02-08 1996-04-10 Chiroscience Ltd Racemisation
US6063284A (en) 1997-05-15 2000-05-16 Em Industries, Inc. Single column closed-loop recycling with periodic intra-profile injection
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6413419B1 (en) 1998-10-29 2002-07-02 Institut Francais Du Petrole Process and device for separation with variable-length chromatographic
US6375839B1 (en) 1998-10-29 2002-04-23 Institut Francais Du Petrole Process and device for separation with variable-length chromatographic zones
FR2785196B1 (fr) 1998-10-29 2000-12-15 Inst Francais Du Petrole Procede et dispositif de separation avec des zones chromatographiques a longueur variable
MXPA02005675A (es) 1999-12-10 2002-09-02 Pfizer Prod Inc Compuestos de pirrolo(2,3-d)pirimidina.
MXPA03004347A (es) * 2000-11-17 2004-05-04 Takeda Chemical Industries Ltd Nuevos derivados de imidazol, metodo de produccion y uso de los mismos.
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
US7427616B2 (en) 2002-08-06 2008-09-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (TEK) activity
JP2004143053A (ja) * 2002-10-22 2004-05-20 Senju Pharmaceut Co Ltd β−アミノヒドロキサム酸誘導体およびその用途
DE60323155D1 (de) * 2002-12-19 2008-10-02 Scripps Research Inst Von transthyretin und zur hemmung von transthyretin-fehlfaltung
JP2005304368A (ja) * 2004-04-21 2005-11-04 Toyo Kasei Kogyo Co Ltd 光学活性な４−（ｎ−保護アミノ）−１−アルケン−３−オールの製造方法、およびそれを用いた３−ベンザミド−２−ヒドロキシカルボン酸またはその塩の製造方法
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
NZ553267A (en) * 2004-07-27 2010-09-30 Sgx Pharmaceuticals Inc Pyrrolo-pyridine kinase modulators
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
AU2006221065A1 (en) 2005-02-03 2006-09-14 Vertex Pharmaceuticals Incorporated Pyrrolopyrimidines useful as inhibitors of protein kinase
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
US20060281755A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
DK1937664T3 (da) 2005-10-14 2011-07-18 Sumitomo Chemical Co Hydrazidforbindelse og pesticid anvendelse af den samme
US20130137681A1 (en) 2005-12-13 2013-05-30 Incyte Corporation HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
PL1966202T3 (pl) 2005-12-13 2012-02-29 Incyte Holdings Corp Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej
KR100815432B1 (ko) * 2005-12-29 2008-03-20 엘아이지엔설팅주식회사 사업 재난 관리 시스템, 방법, 및 상기 방법을 실행시키기위한 컴퓨터 판독 가능한 프로그램을 기록한 매체
AU2007235487A1 (en) * 2006-04-05 2007-10-18 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
DE102006016426A1 (de) * 2006-04-07 2007-10-11 Merck Patent Gmbh Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
WO2008064157A1 (en) 2006-11-22 2008-05-29 Incyte Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
WO2008079965A1 (en) 2006-12-22 2008-07-03 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
KR20080062876A (ko) 2006-12-29 2008-07-03 주식회사 대웅제약 신규한 항진균성 트리아졸 유도체
GB0704932D0 (en) * 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
AU2008237019A1 (en) * 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CN103524509B (zh) 2007-06-13 2016-03-02 因塞特控股公司 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
AR067354A1 (es) * 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
UA104849C2 (uk) 2007-11-16 2014-03-25 Інсайт Корпорейшн 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
BRPI0909040B8 (pt) * 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
MX2010010062A (es) * 2008-03-19 2010-09-30 Bial Portela & Ca Sa Hidrogenacion asimetrica catalitica.
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
IT1393787B1 (it) 2009-03-30 2012-05-08 Cps Color Equipment Spa Dispositivo di erogazione di prodotti fluidi e relativo procedimento di erogazione
AR076920A1 (es) 2009-05-22 2011-07-20 Incyte Corp 3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)octano-o heptano--nitrilo como inhibidores de jak
MX2011012353A (es) 2009-05-22 2011-12-14 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
US9249145B2 (en) * 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EA021478B1 (ru) 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
AU2011217961B2 (en) * 2010-02-18 2016-05-05 Incyte Holdings Corporation Cyclobutane and methylcyclobutane derivatives as Janus kinase inhibitors
LT3354652T (lt) 2010-03-10 2020-09-25 Incyte Holdings Corporation Piperidin-4-il azetidino dariniai kaip jak1 inhibitoriai
TWI499421B (zh) 2010-05-21 2015-09-11 Incyte Corp Ｊａｋ抑制劑的局部製劑
MX344478B (es) 2010-11-19 2016-12-16 Incyte Holdings Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de janus cinasas (jak).
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
US9993480B2 (en) 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak

Also Published As

Publication number Publication date
US20130253191A1 (en) 2013-09-26
TW201718591A (zh) 2017-06-01
KR102138485B1 (ko) 2020-07-27
MX349632B (es) 2017-08-07
KR102220482B1 (ko) 2021-02-25
EP2398774B1 (en) 2017-07-05
JOP20190230A1 (ar) 2017-06-16
NZ739757A (en) 2019-01-25
PL2398774T3 (pl) 2017-11-30
US20210253584A1 (en) 2021-08-19
CA2749483A1 (en) 2010-07-22
TW201524982A (zh) 2015-07-01
EA034207B1 (ru) 2020-01-16
AU2010204772B2 (en) 2016-05-26
PE20211639A1 (es) 2021-08-24
PH12016502060B1 (en) 2017-09-18
TWI720517B (zh) 2021-03-01
CN108395433A (zh) 2018-08-14
AU2010204772A1 (en) 2011-08-04
BR122020005528B1 (pt) 2022-05-17
AU2016216537A1 (en) 2016-09-01
ES2641761T3 (es) 2017-11-13
MA33038B1 (ar) 2012-02-01
KR20210022770A (ko) 2021-03-03
TWI644915B (zh) 2018-12-21
AU2016216537B2 (en) 2018-05-10
IL214061A (en) 2017-06-29
PT3272738T (pt) 2025-01-24
KR20190083010A (ko) 2019-07-10
NZ725585A (en) 2018-05-25
IL242751B (en) 2018-03-29
JP6430464B2 (ja) 2018-11-28
EP3272738A2 (en) 2018-01-24
EA020643B1 (ru) 2014-12-30
IL242750B (en) 2019-06-30
PE20110858A1 (es) 2011-12-04
KR20200095568A (ko) 2020-08-10
JP2017081934A (ja) 2017-05-18
US20130253190A1 (en) 2013-09-26
PE20160788A1 (es) 2016-09-04
IL274422B (en) 2021-06-30
SG10201705183SA (en) 2017-07-28
US20100190981A1 (en) 2010-07-29
AU2022201630A1 (en) 2022-03-31
NZ706894A (en) 2016-11-25
MX383742B (es) 2025-03-14
JP2021100930A (ja) 2021-07-08
JP6843955B2 (ja) 2021-03-17
KR102422043B1 (ko) 2022-07-18
CN105669675A (zh) 2016-06-15
NZ617077A (en) 2015-05-29
IL214061A0 (en) 2011-08-31
TN2011000329A1 (en) 2013-03-27
TW202118766A (zh) 2021-05-16
JP2019048835A (ja) 2019-03-28
JP2012515212A (ja) 2012-07-05
PT2398774T (pt) 2017-09-29
US10364248B2 (en) 2019-07-30
CN102348693A (zh) 2012-02-08
TWI740775B (zh) 2021-09-21
ZA201104909B (en) 2018-11-28
TW202146417A (zh) 2021-12-16
KR20210130846A (ko) 2021-11-01
MX2011007102A (es) 2011-09-15
AU2020201709B2 (en) 2021-12-09
CL2013002617A1 (es) 2014-03-28
KR101999933B1 (ko) 2019-07-12
JOP20190231A1 (ar) 2017-06-16
SG172468A1 (en) 2011-08-29
WO2010083283A2 (en) 2010-07-22
JP6630802B2 (ja) 2020-01-15
WO2010083283A3 (en) 2010-10-14
BRPI1006794A8 (pt) 2017-07-11
AR082747A1 (es) 2013-01-09
EP4501410A2 (en) 2025-02-05
KR20110104119A (ko) 2011-09-21
NZ594057A (en) 2013-11-29
EA201991779A3 (ru) 2020-04-30
KR20220104280A (ko) 2022-07-26
IL274422A (en) 2020-06-30
ECSP11011268A (es) 2011-12-30
EP3272738A3 (en) 2018-04-04
IL267122B (en) 2020-05-31
US8993582B2 (en) 2015-03-31
TWI462924B (zh) 2014-12-01
TW202003521A (zh) 2020-01-16
EP3272738B1 (en) 2024-11-13
JP2020073491A (ja) 2020-05-14
PE20171102A1 (es) 2017-08-07
TWI665200B (zh) 2019-07-11
TW201936608A (zh) 2019-09-16
MX357874B (es) 2018-07-27
BR122020005540B8 (pt) 2021-07-27
CL2016000346A1 (es) 2016-11-25
AU2020201709A1 (en) 2020-03-26
IL267122A (en) 2019-08-29
US20180237442A1 (en) 2018-08-23
EA201400575A1 (ru) 2015-02-27
CA2749483C (en) 2021-07-27
SG10201913261QA (en) 2020-03-30
JP5650662B2 (ja) 2015-01-07
US20250340559A1 (en) 2025-11-06
EA201170935A1 (ru) 2012-02-28
AR127757A2 (es) 2024-02-28
TWI710562B (zh) 2020-11-21
US8883806B2 (en) 2014-11-11
PL3272738T3 (pl) 2025-03-17
US20150218174A1 (en) 2015-08-06
EP4501410A3 (en) 2025-08-06
PH12016502060A1 (en) 2017-09-18
ES3001142T3 (es) 2025-03-04
CL2011001668A1 (es) 2012-02-03
US20130253193A1 (en) 2013-09-26
US20200002341A1 (en) 2020-01-02
KR20180011887A (ko) 2018-02-02
MY186533A (en) 2021-07-25
US20160257687A1 (en) 2016-09-08
US8410265B2 (en) 2013-04-02
MX363976B (es) 2019-04-10
AU2018202625A1 (en) 2018-05-10
CN108395433B (zh) 2024-10-22
IL242752A (en) 2017-06-29
US9000161B2 (en) 2015-04-07
US12247030B2 (en) 2025-03-11
BRPI1006794A2 (pt) 2015-08-25
TWI814080B (zh) 2023-09-01
AU2022201630B2 (en) 2024-04-18
MX2019003989A (es) 2019-08-12
MY163540A (en) 2017-09-15
JP2015091805A (ja) 2015-05-14
US9908888B2 (en) 2018-03-06
KR101824742B1 (ko) 2018-02-01
US10975085B2 (en) 2021-04-13
MY182004A (en) 2021-01-18
KR102318359B1 (ko) 2021-10-27
CN119306753A (zh) 2025-01-14
CO6400137A2 (es) 2012-03-15
US9290506B2 (en) 2016-03-22
TW201038575A (en) 2010-11-01
EP2398774A2 (en) 2011-12-28
CN105669676B (zh) 2018-04-24
CN102348693B (zh) 2016-03-16
CA3121743A1 (en) 2010-07-22
IL283038A (en) 2021-06-30
BR122020005540B1 (pt) 2021-03-02
JP6054355B2 (ja) 2016-12-27
CN105669676A (zh) 2016-06-15
BRPI1006794B1 (pt) 2022-05-17
EA201991779A2 (ru) 2019-12-30
AU2018202625B2 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
JO3441B1 (ar) طرق لاصلاح مثبطات انزيم jak والمركبات الوسيطة المتعلقة به
MX2011004953A (es) Compuestos utiles como inhibidores de cinasa atr.
MX2011006503A (es) Derivados de pirazina utiles como inhibidores de la cinasa de atr.
MX2012013081A (es) Compuestos utiles como inhibidores de cinasa atr.
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011143423A3 (en) Compounds useful as inhibitors of atr kinase
MX2016007371A (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
EA201290878A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ, ПСИХИАТРИЧЕСКИХ И МЕТАБОЛИЧЕСКИХ РАССТРОЙСТВ И ЗАБОЛЕВАНИЙ
WO2011143425A3 (en) Compounds useful as inhibitors of atr kinase
MX2012013082A (es) Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr.
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
EA201290244A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10
TH99326B (th) กรรมวิธีสำหรับการเตรียมตัวยับยั้ง jak และสารประกอบตัวกลางที่เกี่ยวข้อง
TH115252A (th) กรรมวิธีสำหรับการเตรียมตัวยับยั้ง jak และสารประกอบตัวกลางที่เกี่ยวข้อง